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Abstract
Objective: Budd-Chiari syndrome is a multifactorial disease in which several prothrombotic disorders 
may predispose patients to the development of thrombosis at this uncommon location (hepatic veins). 
The aim of this study was to determine the prevalence and characteristics of inherited thrombophilia 
in Egyptian Budd-Chiari syndrome patients.
Materials and Methods: The study included 47 Budd-Chiari syndrome patients (20 children and 27 
adults). Genotyping of Factor V G1691A (Leiden), prothrombin G20210A (PT), and methylenetetra-
hydrofolate reductase C677T were performed using real-time PCR and fluorescence melting curve 
detection analysis.
Results: Factor V Leiden was observed in 29 patients (61.7%). It is the only factor that caused Budd-
Chiari syndrome in 18 of the patients and in 5 of the patients with inferior vena cava involvement. 
Myeloproliferative disease was noted in 12 (25.5%) patients, antiphospholipid syndrome in 5 (10.6%), 
and Behcet’s disease in 3 (6.4%). Interestingly, 3 of the children with Budd-Chiari syndrome had lipid 
storage disease.
Conclusion: Factor V Leiden was a major etiological factor in Egyptian Budd-Chiari syndrome patients, 
which may have been related to the high frequency of this mutation in the study region.  Factor V 
Leiden was also a strong thrombophilic factor and the leading cause of inferior vena cava thrombosis 
in these patients. Lipid storage disease should be included as a risk factor for Budd-Chiari syndrome. 
(Turk J Hematol 2011; 28: 299-305)
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Budd-Chiari syndrome (BCS) is characterized by 
obstruction of the hepatic venous outflow tract in 
the  absence  of  right-sided  heart  failure  and  con-
strictive  pericarditis  [1].  Clinical  manifestations 
include  abdominal  pain,  ascites,  and  liver  and 
spleen enlargement, as well as dilatation of the sub-
cutaneous veins of the trunk in patients with long-
standing inferior vena cava (IVC) obstruction [2].
Primary BCS is a multifactorial disease in which 
several  prothrombotic  disorders  may  predispose 
patients to the development of thrombosis at this 
uncommon location (hepatic veins) [3]. The preva-
lence and cause of BCS vary by geographic region 
[3,4]. Thromboses are prominent etiological factor 
in the West, while webs are more common etiology 
in the East and in Japan [5,6]. In Turkey, Behcet’s 
disease and hydatid disease are more common eti-
ologies [7]. Inherited thrombophilia was reported to 
be a major risk factor in 31% of BCS patients [8]. 
Factor V G1691A (Leiden) (FVL) is considered the 
most common inherited risk factor [9] and the sec-
ond most frequent etiologic factor (following poly-
cythemia vera [PV]) for BCS [10]. The frequency of 
prothrombin  (PT)  G20210A  mutation  igreater  in 
southern  Europe  than  in  northern  Europe,  and  is 
rare  in  the  Middle  East  and  Africa  [11]. 
Hyperhomocysteinemia  and  homozygous  methy-
lenetetrahydrofolate reductase MTHFR C677T muta-
tion were reported to be important risk factors for 
BCS [12]. 
To the best of our knowledge the prevalence and 
effects  of  these  factors  in  Egyptian  BCS  patients 
have not been reported, and few data exist on chil-
dren with BCS. The aim of the present study was to 
determine  the  prevalence  and  characteristics  of 
inherited thrombophilia in both pediatric and adult 
Egyptian BCS patients.
Materials and Methods
The study included 47 consecutive patients (23 
male and 24 female) diagnosed as BCS between 
January  2008  and  January  2010  at  Ain  Shams 
University,  Tropical  Medicine  Clinic,  and  Yassin 
Abdel Ghaffar Charity Center for Liver Disease and 
Research, both of which are major tertiary referral 
centers.  BCS  was  diagnosed  based  on  partial  or 
complete obstruction of hepatic outflow document-
ed via appropriate abdominal radiographic imaging 
(diagnostic  criteria).  Patients  with  veno-occlusive 
disease and those with hepatic outflow obstruction 
caused by congestive heart failure were excluded 
(exclusion criteria) from participating in the study. 
The 47 patients were divided into group 1 (chil-
dren,  n=20)  and  group  2  (adults,  n=27).  All  the 
patients were treated by ≥1 of the authors. The con-
trol group included 130 healthy adult and children 
Egyptian volunteers. Mean age of controls was 31.9 
years (median: 29 years). Controls with a family his-
tory  of  thrombosis  were  excluded.  Genotyping  of 
FVL  G1691A,  prothrombin  G20210A,  and  MTHFR 
Özet
Amaç: Budd-Chiari sendromunun etyolojisinde çok farklı nedenler rol oynayabilir. Farklı protrombotik 
bozukluklar, bu sendromun oluşmasına yol açabilir. Bu çalışmada  Mısır’lı Budd Chiari Sendromu 
tanısı  almış  hastalarda  trombofilik  nedenlerin  sıklığıyla  hastaların  özelliklerinin  karşılaştırılması 
amaçlanmıştır. 
Yöntemler ve Gereçler: Çalışmaya 20 çocuk ve 27 erişkin olmak üzere 47 hasta dahil edilmiştir. Faktör 
V Leiden G1691A, Prothrombin G20210A and methylenetetrahydrofolate reductase C677T genotiple-
meleri gerçek zamanlı polimeraz zincir reaksiyon (PZR) yöntemi kullanılarak gerçekleştirilmiştir. FV 
Leiden toplam 29 hastada (%61.7) saptanmış olup, daha once yapılan çalışmalara göre yüksek bir 
orandır. 18 hastada Budd Chiari sendromu oluşması için tek etyolojik neden olarak göze çarpmaktadır. 
Myeloproliferatif hastalık sadece 12 (%25.5), antifosfolipid sendromu 5 (%10.6), ve Behçet hastalığı 
3 (%6.4) hastada saptanmıştır. İlginç olan 3 çocukta lipid depo hastalıkların da belirlenmiş olmasıdır. 
Sonuç: Faktör V Leiden'ın Budd Chiarinin oluşmasındaki temel etyolojik faktörlerden biri olarak göze 
çarpmaktadır. Bu ise mutasyonun Mısır toplumunda yüksek oranda bulunmasına bağlanabilir. Lipid 
depo hastalıklarının da Budd Chiari için risk faktörü olarak dahil edilmesi gerekmektedir. 
(Turk J Hematol 2011; 28: 299-305)
Anahtar kelimeler: Budd- Chiari sendromu, thrombofili, Factor V Leiden, prothrombin, methylene-
tetrahydrofolate, Niemann-Pick, gaucher, Behçet sendromu, thromboz
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protocol was approved by the ethical committee of 
both  Yassin  Abdelghaffar  Charity  Center  for  Liver 
Diseases and Research and Ain Shams University. 
An informed consent was obtained from the adult 
patients and controls, and from the parents of the 
pediatric patients. Medical history and family histo-
ry  of  spontaneous  deep  venous  thrombosis  and 
acquired risk factors for BCS, such as use of oral 
contraceptive pills and pregnancy, were recorded 
for each patient. 
Protein C, protein S, and antithrombin III levels, 
lupus anticoagulant, and anticardiolipin antibodies 
were measured in all the patients for detection of 
antiphospholipid  syndrome  (APL).  Patients  with 
heterozygous JAK2 V617F mutation were diagnosed 
as myeloproliferative disease (MPD). Diagnosis of 
Niemann-Pick  disease  (NPD)  was  based  on  low 
acid sphingomyelinase activity (<5% of normal) in 
isolated leukocytes and Gaucher disease (GD) was 
diagnosed  based  on  low  β-  glucocerebrosidase 
activity (<5% of normal) in isolated leukocytes.
DNA was isolated using a Magna Pure Automatic 
Isolation System (Roche Diagnostics, Indianapolis, 
USA).  Genotyping  of  FVL  G1691A,  prothrombin 
G20210A, and MTHFR C677 was performed via real-
time PCR and fluorescence melting curve detection 
analysis  using  a  Light  Cycler  System  (Roche 
Diagnostics,  Manheim,  Germany);  primers  were 
obtained from TIB MOLBION (Berlin, Germany). 
Statistical methods
SPSS  for  Windows  v.13.0  (SPSS  Inc,  USA)  was 
used for data entry and analysis. All numeric vari-
ables are expressed as mean±standard deviation 
(SD). Comparison of variables between groups was 
performed  using  Student’s  t  test  and  the  Mann-
Whitney U test was used for normal and nonpara-
metric variables. The chi-square (χ2) test was used 
to compare the frequency of qualitative variables 
between groups. Spearman’s correlation test was 
used  to  determine  the  correlation  between  non-
parametric variables. For all tests a p value <0.05 
was considered statistically significant [13].
Results 
Patient  characteristics  are  shown  in  Table  1. 
Ascites was significantly more common in the adult 
patients,  whereas  dilated  abdominal  veins  were 
significantly more common in the pediatric patients. 
Medical history and family history of spontaneous 
deep venous thrombosis were negative in all the 
patients. BCS was not associated with pregnancy or 
use of oral contraceptive pills in any of the adult 
female patients. Inherited thrombophilia mutations 
(FVL and PT) were noted in 30 (63.8%) patients (29 
with FVL and 1 with PT). The frequency of FVL was 
significantly higher in the BCS patients (no signifi-
cant  difference  between  pediatric  and  adult 
patients) than in the controls (Table 2). Furthermore, 
FVL was the only etiological factor for BCS in 18 of 
the patients (Table 3). None of the patients had pro-
tein C, protein S, or antithrombin III deficiency. All 
patients  with  MPD  had  heterozygous  JAK2  V617F 
mutation.
Comparison  of  the  patients  with  and  without 
inherited  thrombophilia  mutations  showed  that 
dilated abdominal veins, ascites, and encephalopa-
thy were more common in the patients with muta-
tions, whereas jaundice was more common in those 
without  mutations,  although  the  differences  were 
not statistically significant. Hepatic vein thrombosis 
was observed in 33 patients (70.2%), IVC thrombosis 
was observed in only 3 patients (6.4%), and both 
were observed in 11 patients (23.4%). IVC involve-
ment was observed in 14 patients (29.8%), 45% of 
which  were  children  (9/20);  FVL  mutation  was 
noted in 50% of these 14 patients (n=7) (Table 4). 
Discussion
The present study shows that FVL was a major 
etiological  factor  for  thrombosis  in  Egyptian  BCS 
patients; 61.7% of patients in the present study had 
FVL, as compared to previous reports of 26%-36% on 
different poulations [1,14]. This might have been due 
the high frequency of FVL in the study region [15]. In 
Egyptian children, FVL was previously reported to 
be  the  most  common  factor  in  Egyptian  children 
with  portal  vein  thrombosis,  although  to  a  lesser 
extent (30%) [16]. This may be explained to the dif-
ference  in  the  site  of  thrombosis  (hepatic  veins 
versus portal veins). In the present study, FVL alone 
(without other acquired factors) caused BCS in 18 
of  the  patients  and  in  50%  of  patients  with  IVC 
involvement (as not all patients with BCS have IVC 
involvement), which contradicts the notion that is a 
relatively weak thrombotic factor and the assump-
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cause thrombosis. 
Another interesting finding of the present study is 
that 3 of the BCS patients had lipid storage disease   
(2 patients had GD and 1 had NPD), of which only one 
with GD had FVL. There is only one report of BCS in 
Gaucher disease patients [17] and no report of BCS in 
NPD patients. A possible explanation of hepatic vein 
obstruction in these patients is arterial thickening or 
narrowing secondary to swelling of the medial and 
intimal smooth-muscle cells which is supported by 
the autopsy findings in these patients [18]. 
On the other hand, in this study, only 1 patient 
had PT mutation, which is in agreement with previ-
ous  reports  indicating  that  this  mutation  is  not  a 
prominent etiological factor in BCS patients [1,19].
In  the  present  study  MTHFR  C677T  occurred 
more frequently in the adult patients than both chil-
dren  and  controls,  whereas  homozygosity  of  this 
mutation  occurred  less  frequently  in  the  adult 
patients than in the controls, which indicates that it 
is not a strong thrombotic factor unless augmented 
by another acquired or hereditary risk factor. JAK2 
V617F mutation-positive MPD was observed in only 
Table 1. Patient Characteristics
  Children (n=20)  Adults (n=27)  P
Gender: Male/female  12/8  11/16  0.244
Mean age at presentation (years)  12.6±5.5   30.7±6.9   0.001
Presentation (%) 
Acute/subacute  42.1  25.9  0.209
Chronic  57.9  74.1 
Presenting symptoms (%) 
Abdominal pain  63.2  77.8  0.331
Abdominal distension  68.4  96.3  0.15
Jaundice  10.5  14.8  1.0
Accidental  5.5  3.7 
Others*  0.0  7.4 
Physical examination results (%)
Hepatomegaly  84.2  88.9  0.68
Splenomegaly  52.6  44.4  0.765
Jaundice  21.1  22.2  1.0
Ascites  57.9  92.3  0.01
Dilated abdominal veins  52.6  14.8  0.009
LL edema  13.3  7.4  0.608
Encephalopathy  5.5  11.1  1.0
GIT bleeding  5.5  3.7  1.0
Laboratory results (mean±SD) 
Total Bilirubin (mg, %)  3.8±8.7  2.5±2.1  0.445
Direct bilirubin (mg, %)  2.3±5.9  1.1±0.9  0.227
ALT (xN)  2.1±3.4  2.3±2.3  0.842
AST (xN)  2.8±3.9  2.8±4.5  1.0
INR  1.6±0.6  1.3±0.2  0.29
Albumin (g/dL)  3.3±0.7  3.4±0.6  0.072
Course (%) 
Regressive   17.6  25  0.602
Stable   52.9  37.5 
Progressive   11.8  25 
Death   17.6  12.5 
*Others: GIT bleeding, LL edema, xN: multiple of normal
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lower  frequency  than  previously  reported  in  BCS 
[20,21].  Acquired  factors,  including  Behcet’s  dis-
ease,  were  noted  in  7.4%  of  the  presented  adult 
patients, which is similar to the frequency reported 
in Turkey (9%) [7], a country which has a long his-
torical background with Egypt; among these patients, 
1 had pure involvement of the hepatic veins without 
IVC involvement, which is a rare finding [22].
In the present study the male to female patient 
ratio was close to one (1.04:1); which is consistent 
with  that  reported  by  the  European  Network  for 
Vascular Disorders of the Liver [23].
In  conclusion,  FVL  (independently  causing 
hypercoagulopathy  or  as  a  cofactor  in  different 
disease states) was a prominent etiological factor 
for BCS in our Egyptian patient population, most 
likely due to the prevalence of this mutation in the 
study  region  [15].  It  was  a  strong  thrombophilic 
factor and the leading cause of IVC thrombosis in 
the presented BCS patients, which is in contrast 
with PT and MTHFR, both of which had little effect 
on thrombosis in the BCS patients. Lipid storage 
disease may be considered a risk factor for BCS. 
Appropriate risk assessment should include com-
plete  thrombophilia  screening  in  patients  with 
BCS, even in the presence of overt acquired throm-
botic risk factors. 
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Table 2. Distribution of FVL, PT, and MTHFR Gene Mutations
  n  FVL  PT  MTHFR
    G/A (%)  A/A (%)  G/A (%)  C/T (%)  T/T (%)
Children  20  10 (50)  3 (15)  0 (0)  6 (30)  1 (5)
Adults  27  14 (51.9)  2 (7.4)  1 (3.7)  13 (48.1)  1 (3.7)
Controls*  130  18 (13.8)  0 (0)  0 (0)  23 (25.5)  7 (7.8)
*MTHFR was done to only 90 controls
Table 3. The Prevalence of Major Risk Factors in the BCS Patients
Risk factor    Children  Adults  Total 
    (n)  (n)  (%)
FVL  Alone   10  8  18 (38.3)
  With other risk factors   3  8  11 (23.4)
PT mutation   Alone  0  1  1 (2.1)
MPD  Alone   1  6  7 (14.9)
  With FVL   1  4  5 (10.6)
APL  Alone   1  0  1 (2.1)
  With FVL   1  3  4 (8.5)
Behcet disease  Alone   1  1  2 (4.2)
  With FVL   0  1  1 (2.1)
Lipid storage disease  Alone   2  0  2(4.2)
  With FVL   1  0  1 (2.1)
No factor detected    2  3  5 (10.6)
APS: Antiphospholipid syndrome; FVL: factor V Leiden; MPD: myeloproliferative disease; NP: Niemann-Pick disease
Table 4. The Prevalence of Major Risk Factors in the BCS Patients with 
IVC İnvolvement
    n  Total(%)
FVL   Alone   5  5 (35.7)
  With other risk factors   2  2 (14.3)
MPD  Alone  2  2 (14.3)
APL  Alone  1  2 (14.3)
  With FVL  1 
Behcet disease  Alone  1  2 (14.3)
  With FVL  1 
NPD  Alone  1  1 (7.1)
No apparent factor  2  2 (14.3)
APS: Antiphospholipid syndrome; FVL: factor V Leiden; MPD: myeloprolifera-
tive disease; NP: Niemann-Pick disease
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